A promising new targeted cancer therapy is now available to certain patients with advanced pancreatic cancer – from the comfort of their home. The treatment is available through a first-of-its-kind, ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

As of Monday, November 10, Cogent Biosciences, Inc.’s COGT share price has surged by 136.17%, which has investors questioning if this is right time to sell.

Largest prospective clinical trial to-date in a rare subtype of GISTROCKVILLE, Md. and SUZHOU, China, (GLOBE NEWSWIRE) -- ...

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT stock and why I am bullish.

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics Market, which increased ...

Tyra Bioscience, Inc ( (TYRA)) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors. Tyra Biosciences, Inc. is a clinical-stage ...

Primary central nervous system (CNS) tumors pose significant challenges due to their heterogeneous nature, frequently limited prognosis, and substantial impact on quality of life. Despite advances in ...